Biochemicals and Reagents

Selonsertib hydrochloride is a potent ASK1 (Apoptosis signal-regulating kinase 1) inhibitor, which is a targeted small molecule therapeutic derived from chemical synthesis. Its mode of action involves the inhibition of ASK1, a kinase enzyme involved in cellular apoptosis and inflammation pathways. Specifically, ASK1 is upstream in the MAPK signaling cascade that modulates oxidative stress responses, often implicated in various pathological states.

WHI-P180 is a potential anticancer agent that has been shown to be effective in inhibiting the growth of human colon cancer cells (HCT116) and CD-1 mice with cancer. WHI-P180 binds to the intracellular targets of mcf-7, a growth factor involved in cell proliferation, which leads to neuronal death. This agent has also been demonstrated to be cytotoxic against monoclonal antibodies and epidermal growth factor receptor (EGFR). WHI-P180 targets ABCG2, an enzyme involved in drug efflux, which may lead to increased efficacy of this drug.

3-(4-Methoxyphenyl)-N-(2-morpholin-4-ylpyrimidin-4-yl)-1,2-oxazol-5-amine is a networked interface that provides information on the drug's chemical structure, molecular weight, and 3D molecular structure. It also provides information on related drugs, as well as drug targets.

Carbasulam is an anticancer drug that inhibits the growth of cancer cells by inducing apoptosis. It acts by binding to protein kinases, which are enzymes that play a crucial role in cell signaling and regulation. Carbasulam has been shown to be effective in inhibiting the growth of tumors in human and Chinese hamster ovary cells. It is a medicinal analog of urine-derived kinase inhibitors, which have been used as potential anticancer agents. Carbasulam is a potent inhibitor of several kinases involved in cancer cell proliferation, including Akt, ERK1/2, and JNK1/2. Its ability to selectively target these kinases makes it a promising candidate for the treatment of various types of cancer.

SK-216 is a small molecule that inhibits the activation of FoxO1, which is a transcription factor. SK-216 also prevents oxidative injury and mitochondrial dysfunction by inhibiting the production of growth factor-β1, as well as inhibiting the activation of Toll-like receptor 2 (TLR2) and TLR4. SK-216 has been shown to have anti-inflammatory effects and can inhibit cyclin D2 expression, which leads to inhibition of energy metabolism in cancer cells. SK-216 also has an effect on epithelial mesenchymal transition (EMT), leading to suppression of EMT, tumorigenesis, migration, and metastasis.

2B-(SP) is a monoclonal antibody that inhibits the phosphorylation of proteins by inhibiting the activity of protein phosphatase. This, in turn, prevents activation of tyrosine kinases and blocks dopamine-induced locomotor activity. 2B-(SP) also blocks cholinergic signaling in h9c2 cells, which may be due to its ability to inhibit the enzyme acetylcholinesterase. 2B-(SP) has been shown to inhibit cardiac hypertrophy in vivo, as well as cardiac fibrosis and cardiomyopathy in rats.

Arphamenine B is a potent, selective, and reversible inhibitor of the protein tyrosine phosphatase 1B (PTP1B). Arphamenine B binds to PTP1B with high affinity and specificity. It is a useful tool for studying protein-protein interactions and protein function. Arphamenine B can also be used as an activator or ligand for receptors, especially G-protein coupled receptors. This peptide has been shown to inhibit ion channels such as calcium channels, potassium channels, and sodium channels.

MonoFITC INSL4 is a peptide that is used as a research tool. It is an activator of the Insulin-like Growth Factor Receptor 4 (IGF-1R) and can be used to study the protein interactions of the receptor. MonoFITC INSL4 has shown to inhibit the binding of insulin and IGF-1, which are ligands for the receptor. This peptide has also been shown to activate phosphatidylinositol 3-kinase, which is a cellular signalling pathway involved in many cellular processes such as proliferation and apoptosis.